SEC Filing Summary: Pieris Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K Current Report was filed by Pieris Pharmaceuticals, Inc. on July 5, 2017, regarding events occurring on June 30, 2017. The filing details the results of the Company's Annual Meeting of Stockholders. Note: The input metadata references "Palvella Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Pieris Pharmaceuticals, Inc.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
On June 30, 2017, the Company held its Annual Meeting. A quorum was established with 28,580,484 shares (66.37% of the 43,058,827 eligible shares) present in person or by proxy. The following actions were taken:
- Director Elections: Stephen S. Yoder and Michael Richman were reelected as Class III Directors to serve until the 2020 annual meeting.
- Accounting Firm Ratification: The selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2016, was ratified.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the correct registrant name is Pieris Pharmaceuticals, Inc., not Palvella Therapeutics, Inc.
- Confirm the re-election of Stephen S. Yoder and Michael Richman to the Board of Directors.
- Note the ratification of Ernst & Young LLP as the auditor for the fiscal year ending December 31, 2016.
- Observe that 13,923,689 broker non-votes were recorded for the director elections.